@article{pmid28975560,

title = {Observational study of potential risk factors of immersion pulmonary edema in healthy divers: exercise intensity is the main contributor},

author = {A Boussuges and K Ayme and G Chaumet and E Albier and M Borgnetta and O Gavarry},

doi = {10.1186/s40798-017-0104-1},

issn = {2199-1170},

year  = {2017},

date = {2017-10-01},

urldate = {2017-10-01},

journal = {Sports Med Open},

volume = {3},

number = {1},

pages = {35},

abstract = {BACKGROUND: The risk factors of pulmonary edema induced by diving in healthy subjects are not well known. The aim of the present study was to assess the parameters contributing to the increase in extravascular lung water after diving.



METHODS: This study was carried out in a professional diving institute. All divers participating in the teaching program from June 2012 to June 2014 were included in the study. Extravascular lung water was assessed using the detection of ultrasound lung comets (ULC) by chest ultrasonography. Clinical parameters and dive profiles were recorded using a questionnaire and a dive computer.



RESULTS: One-hundred six divers were investigated after 263 dives. They used an open-circuit umbilical supplying compressed gas diving apparatus in 202 cases and a self-contained underwater breathing apparatus in 61 cases. A generalized linear mixed model analysis was performed which demonstrated that the dive induced a significant increase in ULC score (incidence rate ratio: 3.16). It also identified that the predictive variable of increased extravascular lung water after the dive was the exercise intensity at depth (z = 3.99, p < 0.0001). The other parameters studied such as the water temperature, dive profile, hyperoxic exposure, or anthropometric data were not associated with the increase in extravascular lung water after the dive.



CONCLUSIONS: In this study, the exercise intensity was the main contributor to the increase in extravascular lung water in healthy divers. To improve the prevention of immersion pulmonary edema, the exercise intensity experienced during the dive should thus be adapted to the aerobic fitness level of the divers.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Bauer2017-hi,

title = {MMP-7 is a predictive biomarker of disease progression in  patients with idiopathic pulmonary fibrosis},

author = {Yasmina Bauer and Eric S White and Simon Bernard and Peter Cornelisse and Isabelle Leconte and Adele Morganti and Sebastien Roux and Oliver Nayler},

doi = {10.1183/23120541.00074-2016},

year  = {2017},

date = {2017-01-01},

urldate = {2017-01-01},

journal = {ERJ Open Res.},

volume = {3},

number = {1},

pages = {00074--02016},

publisher = {European Respiratory Society (ERS)},

abstract = {Idiopathic pulmonary fibrosis (IPF) is a progressive 

 interstitial lung disease with poor prognosis, which is 

 characterised by destruction of normal lung architecture and 

 excessive deposition of lung extracellular matrix. The 

 heterogeneity of disease progression in patients with IPF poses 

 significant obstacles to patient care and prevents efficient 

 development of novel therapeutic interventions. Blood 

 biomarkers, reflecting pathobiological processes in the lung, 

 could provide objective evidence of the underlying disease. 

 Longitudinally collected serum samples from the Bosentan Use in 

 Interstitial Lung Disease (BUILD)-3 trial were used to measure 

 four biomarkers (metalloproteinase-7 (MMP-7), Fas death receptor 

 ligand, osteopontin and procollagen type I C-peptide), to assess 

 their potential prognostic capabilities and to follow changes 

 during disease progression in patients with IPF. In baseline 

 BUILD-3 samples, only MMP-7 showed clearly elevated protein 

 levels compared with samples from healthy controls, and further 

 investigations demonstrated that MMP-7 levels also increased 

 over time. Baseline levels of MMP-7 were able to predict 

 patients who had higher risk of worsening and, notably, baseline 

 levels of MMP-7 could predict changes in FVC as early as month 

 4. MMP-7 shows potential to be a reliable predictor of lung 

 function decline and disease progression.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}